[go: up one dir, main page]

NO20080359L - Krystallinsk base av escitalopram og orodispergerbare tabletter omfattende escitalopram base - Google Patents

Krystallinsk base av escitalopram og orodispergerbare tabletter omfattende escitalopram base

Info

Publication number
NO20080359L
NO20080359L NO20080359A NO20080359A NO20080359L NO 20080359 L NO20080359 L NO 20080359L NO 20080359 A NO20080359 A NO 20080359A NO 20080359 A NO20080359 A NO 20080359A NO 20080359 L NO20080359 L NO 20080359L
Authority
NO
Norway
Prior art keywords
escitalopram
base
salts
crystalline
oxalate
Prior art date
Application number
NO20080359A
Other languages
English (en)
Inventor
Hans Petersen
Ole Nielsen
Michael Harold Rock
Robert Dancer
Helle Eliasen
Ken Lijegren
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37546630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080359(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20080359L publication Critical patent/NO20080359L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår den krystallinske basen av det godt kjente antidepressive legemiddelet escitalopram, S-1-[3-(dimetylamino)propyl]-1-(4-fluorofenyl)-1,3-dihydro-5-isobezofurankarbonitril, formuleringer av nevnte base, en fremgangsmåte for fremstilling av rensede salter av escitalopram, slik som oksalatet, ved anvendelse av basen, saltene oppnådd ved nevnte fremgangsmåte og formuleringer som inneholder slike salter, og en fremgangsmåte for fremstilling av renset escitalopram fri base eller salter av escitalopram, slik som oksalatet, ved anvendelse av hydrobromidet, saltene oppnådd ved nevnte fremgangsmåte og formuleringer som inneholder slike salter. Til slutt angår foreliggende oppfinnelsen en orodispergerbar tablett som har en hardhet på minst 22 N og en oral desintegreringstid på mindre enn 120 s og som innebefatter én aktiv farmasøytisk ingrediens adsorbert på et vannløselig fyllstoff hvori den aktive farmasøytiske ingrediensen har et smeltepunkt i området 40-100 °C, så vel som en fremgangsmåte for fremstilling av en orodispergerbar tablett.
NO20080359A 2005-06-22 2008-01-18 Krystallinsk base av escitalopram og orodispergerbare tabletter omfattende escitalopram base NO20080359L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500912 2005-06-22
PCT/DK2006/000366 WO2006136169A2 (en) 2005-06-22 2006-06-22 Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base

Publications (1)

Publication Number Publication Date
NO20080359L true NO20080359L (no) 2008-01-18

Family

ID=37546630

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20080359A NO20080359L (no) 2005-06-22 2008-01-18 Krystallinsk base av escitalopram og orodispergerbare tabletter omfattende escitalopram base
NO20101777A NO20101777L (no) 2005-06-22 2010-12-20 Orodispergerbare tabletter

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20101777A NO20101777L (no) 2005-06-22 2010-12-20 Orodispergerbare tabletter

Country Status (39)

Country Link
EP (3) EP1896439B2 (no)
JP (5) JP4906852B2 (no)
KR (5) KR20120064140A (no)
CN (2) CN101189220A (no)
AR (2) AR055062A1 (no)
AT (3) AT10983U1 (no)
AU (2) AU2006261452B2 (no)
BG (1) BG66086B1 (no)
BR (1) BRPI0612295A2 (no)
CA (2) CA2612827C (no)
CY (1) CY1112392T1 (no)
CZ (3) CZ301286B6 (no)
DE (2) DE112006001619T5 (no)
DK (3) DK1896439T4 (no)
EA (2) EA201001108A1 (no)
EE (1) EE00773U1 (no)
ES (2) ES2319073B1 (no)
FI (2) FI20080548L (no)
GB (2) GB2442160B (no)
HR (1) HRP20110093T4 (no)
HU (1) HUP0800135A3 (no)
IL (1) IL187454A0 (no)
IS (1) IS8705A (no)
LT (1) LT5550B (no)
LV (1) LV13677B (no)
MX (1) MX2007015328A (no)
MY (2) MY143252A (no)
NO (2) NO20080359L (no)
PL (2) PL1896439T5 (no)
PT (1) PT1896439E (no)
RS (1) RS51575B2 (no)
SG (1) SG169358A1 (no)
SI (1) SI1896439T2 (no)
SK (1) SK500402007A3 (no)
TR (2) TR200708792T1 (no)
TW (2) TWI347942B (no)
UA (1) UA86536C2 (no)
WO (1) WO2006136169A2 (no)
ZA (2) ZA200711066B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
EP2134325A2 (en) * 2007-03-01 2009-12-23 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
ME02391B (me) 2010-07-23 2016-09-20 H Lundbeck As Postupak za prečišćavanje farmaceutski prihvatljivih soli escitaloprama
CN103360353A (zh) * 2013-08-07 2013-10-23 中国药科大学 草酸艾司西酞普兰杂质的制备方法
JP2018016569A (ja) * 2016-07-26 2018-02-01 株式会社トクヤマ （１ｓ）−１−［３−（ジメチルアミノ）プロピル］−１−（４−フルオロフェニル）−１，３−ジヒドロイソベンゾフラン−５−カルボニトリル蓚酸塩の製造方法
WO2018190294A1 (ja) * 2017-04-10 2018-10-18 東和薬品株式会社 エスシタロプラム医薬組成物
CN110711198B (zh) * 2018-07-12 2022-03-15 山东大学 D-甘露糖在制备抗抑郁药物中的应用
KR102331187B1 (ko) 2019-04-09 2021-11-26 주식회사 라이트팜텍 에스시탈로프람을 함유하는 안정성이 우수한 경구용 액제 조성물 및 그의 제조방법
WO2022153262A1 (en) * 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
JPH05222041A (ja) * 1992-02-13 1993-08-31 Mitsubishi Gas Chem Co Inc アデニン誘導体の精製法
AU680345B2 (en) * 1994-01-27 1997-07-24 Board Of Regents Of The University Of Oklahoma, The Rapidly dissolving oral dosage form
US5607697A (en) * 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
DE69717317T2 (de) 1997-06-30 2003-10-02 Beloit Technologies, Inc. Verfahren und vorrichtung zum auftragen einer beschichtung auf eine bei hoher geschwindigkeit laufende papierbahn
DE69801764T2 (de) 1997-07-08 2002-07-04 H. Lundbeck A/S, Kobenhavn-Valby Verfahren zur herstellung von citalopram
WO1998019512A2 (en) 1997-11-11 1998-05-14 H. Lundbeck A/S Method for the preparation of citalopram
FR2785538B1 (fr) * 1998-11-06 2004-04-09 Prographarm Laboratoires Comprime a delitement rapide perfectionne
US20020071864A1 (en) * 1999-03-25 2002-06-13 Yuhan Corporation Rapidly disintegrable tablet for oral administration
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
JP2001226372A (ja) * 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd ロサルタンの結晶性または結晶化された酸付加塩およびロサルタンの精製方法
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
AU2001294192A1 (en) * 2000-10-06 2002-04-22 Takeda Chemical Industries Ltd. Solid preparations
JP4446463B2 (ja) * 2000-10-16 2010-04-07 第一三共株式会社 口腔内速崩壊性医薬組成物およびその製造方法
US7799342B2 (en) 2000-12-06 2010-09-21 Wyeth Llc Fast dissolving tablet
HK1048812B (zh) * 2000-12-22 2007-06-01 H‧隆德贝克有限公司 制备纯西酞普兰的方法
AU3920201A (en) * 2000-12-28 2001-07-09 H. Lundbeck A/S Process for the preparation of pure citalopram
YU85303A (sh) * 2001-05-01 2006-05-25 H. Lundbeck A/S Upotreba enantiomerno čistog escitaloprama
US6872405B2 (en) * 2001-05-10 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. Quick-disintegrating tablet in buccal cavity and manufacturing method thereof
GB0113842D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
EP1522539B1 (en) * 2001-07-31 2007-01-24 H. Lundbeck A/S Crystalline composition containing escitalopram
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2003057132A2 (en) * 2002-01-07 2003-07-17 Sun Pharmaceutical Industries Limited Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
AU2003225285A1 (en) * 2002-05-03 2003-11-17 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
ATE388947T1 (de) 2002-12-23 2008-03-15 Lundbeck & Co As H Escitalopramhydrobromid und ein verfahren zu dessen herstellung
CN1510024A (zh) * 2002-12-24 2004-07-07 北京德众万全药物技术开发有限公司 可用于制备西酞普兰(s)-对映异构体的新的化合物及其制备方法
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
AU2004238321B2 (en) * 2003-05-07 2009-08-27 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
WO2005037254A1 (ja) * 2003-10-15 2005-04-28 Fuji Chemical Industry Co., Ltd. 口腔内速崩壊性錠剤
AU2003282383A1 (en) * 2003-11-20 2005-06-08 Natco Pharma Limited A process for the preparation of high purity escitalopram
HU227491B1 (en) * 2003-11-25 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Tablet containing citalopram hydrogen bromide
CA2558198A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
WO2006106531A1 (en) * 2005-04-04 2006-10-12 Jubilant Organosys Ltd Process for the preparation of escitalopram or its acid addition salts

Also Published As

Publication number Publication date
DK200800075A (da) 2008-03-15
AR055062A1 (es) 2007-08-01
MY143239A (en) 2011-04-15
MY143252A (en) 2011-04-15
AR079750A2 (es) 2012-02-15
EP2385044A1 (en) 2011-11-09
ES2319073B1 (es) 2010-02-26
ES2356838T3 (es) 2011-04-13
FI20080548A7 (fi) 2008-10-07
FI20077133A7 (fi) 2007-12-20
EP1896439B1 (en) 2011-02-02
GB2442160A (en) 2008-03-26
CN101928269A (zh) 2010-12-29
AU2006261452B2 (en) 2010-02-04
KR101340815B1 (ko) 2013-12-11
EE00773U1 (et) 2008-10-15
PL1896439T3 (pl) 2011-04-29
KR20120064140A (ko) 2012-06-18
AU2006261452A1 (en) 2006-12-28
TR200708792T1 (tr) 2008-05-21
JP4415056B2 (ja) 2010-02-17
DE112006001619T5 (de) 2008-06-12
CA2612827A1 (en) 2006-12-28
JP2009179634A (ja) 2009-08-13
DK200900284A (da) 2009-02-27
FI20077133L (fi) 2007-12-20
AU2010200844A1 (en) 2010-04-01
MX2007015328A (es) 2008-02-15
ATE497500T1 (de) 2011-02-15
CZ2007898A3 (cs) 2008-01-23
CZ301286B6 (cs) 2009-12-30
CY1112392T1 (el) 2015-12-09
WO2006136169A2 (en) 2006-12-28
PL1896439T5 (pl) 2016-01-29
UA86536C2 (ru) 2009-04-27
HRP20110093T4 (hr) 2015-02-27
CZ300686B6 (cs) 2009-07-15
ES2356838T5 (es) 2015-01-26
CZ299906B6 (cs) 2008-12-29
HUP0800135A2 (en) 2008-06-30
TWI358407B (en) 2012-02-21
BG66086B1 (bg) 2011-03-31
TW201130808A (en) 2011-09-16
EP1896439B2 (en) 2014-10-15
GB2448834B (en) 2010-01-20
ZA200711066B (en) 2009-07-29
NO20101777L (no) 2008-01-18
IS8705A (is) 2008-01-14
DE602006019961D1 (de) 2011-03-17
TW200740785A (en) 2007-11-01
BG110024A (bg) 2008-05-30
SK500402007A3 (sk) 2008-05-06
AT10983U1 (de) 2010-02-15
TR201000625T1 (tr) 2010-03-22
ZA200901698B (en) 2010-04-28
PL384185A1 (pl) 2008-06-23
DK1896439T3 (da) 2011-02-28
RS51575B (sr) 2011-08-31
CA2612827C (en) 2010-11-30
TWI347942B (en) 2011-09-01
LV13677B (en) 2008-05-20
EA200800102A1 (ru) 2008-04-28
GB0811164D0 (en) 2008-07-23
EP2325177A1 (en) 2011-05-25
CA2646780A1 (en) 2006-12-28
JP5731957B2 (ja) 2015-06-10
SI1896439T2 (sl) 2014-12-31
WO2006136169A3 (en) 2007-10-18
KR20110033310A (ko) 2011-03-30
CN101189220A (zh) 2008-05-28
JP2009179635A (ja) 2009-08-13
DK1896439T4 (en) 2015-01-12
KR20110084341A (ko) 2011-07-21
RS51575B2 (sr) 2018-02-28
JP2009046506A (ja) 2009-03-05
KR20080018191A (ko) 2008-02-27
LT5550B (lt) 2009-03-25
GB2448834A (en) 2008-10-29
ES2319073A1 (es) 2009-05-01
FI20080548L (fi) 2008-10-07
KR20100133023A (ko) 2010-12-20
SG169358A1 (en) 2011-03-30
PT1896439E (pt) 2011-02-15
EA201001108A1 (ru) 2011-02-28
GB0724557D0 (en) 2008-01-23
BRPI0612295A2 (pt) 2011-01-04
LT2008005A (en) 2008-10-27
JP4906852B2 (ja) 2012-03-28
AT11883U1 (de) 2011-06-15
JP2008546724A (ja) 2008-12-25
EA019239B1 (ru) 2014-02-28
IL187454A0 (en) 2008-02-09
HRP20110093T1 (hr) 2011-03-31
SI1896439T1 (sl) 2011-03-31
JP2012072168A (ja) 2012-04-12
HUP0800135A3 (en) 2009-01-28
EP1896439A2 (en) 2008-03-12
GB2442160B (en) 2010-01-20

Similar Documents

Publication Publication Date Title
NO20080359L (no) Krystallinsk base av escitalopram og orodispergerbare tabletter omfattende escitalopram base
CA2360287A1 (en) Crystalline base of citalopram
JP2010525084A5 (no)
NO20071667L (no) Farmasoytisk preparat omfattende levetiracetam og fremgangsmate for fremstilling av preparatet
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
NO20045072L (no) Tablett med hoyt medikamentinnhold
NO20083104L (no) Fast preparat
CA2640451A1 (en) Medicine for transnasal administration
MA29744B1 (fr) Formulations posologiques solides de medicaments presentant une adsorption buccale amelioree
DK1675591T3 (da) Farmaceutisk sammensætning omfattende en monoamin-neurotransmitter-genoptagelseshæmmer og en acetylcholinesterase-hæmmer
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
NO20045126L (no) N-acyl piperidinderivater for anvendelse som melanokortinreseptorligander i behandling av fodeforstyrrelser
EA200501697A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
WO2007144080A3 (de) Antidepressiva-kombinations-wafer
RU2008102238A (ru) Таблетка, содержащая труднорастворимый активный ингредиент
CA2443019A1 (en) Kappa-opiate agonists for the treatment of bladder diseases
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
TH98476A (th) เบสที่เป็นผลึกของเอสซิทาโลแปรม และยาเม็ดกระจายตัวในปากซึ่งประกอบรวมด้วยเอสซิทาโลแปรมเบส
EA201070175A1 (ru) Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид
AR104921A2 (es) Formulación farmacéutica con liberación retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol o una sal farmacéuticamente aceptable del mismo y tabletas para administración oral, que la contienen
UY28251A1 (es) Uso del hidrocloruro de la base del principio activo 1-(n2-(3,5-dibromo-n-((4-(3,4-dihidro-2 (1h)- oxoquinazolin-3-il)-1-piperidinil)-carbonil)-d-tirosil)-l-lisil)-4-(4-pipperidin)-piperazina en combinación con sumatriptano para el tratamiento de la
TH98476B (th) เบสที่เป็นผลึกของเอสซิทาโลแปรม และยาเม็ดกระจายตัวในปากซึ่งประกอบรวมด้วยเอสซิทาโลแปรมเบส
NO20062810L (no) Fast farmasoytisk preparatform
Baldwin et al. P. 2. c. 013 A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in MDD treatment

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104